Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NFC-1 in adolescents with ADHD and mGluR gene disruptions
NCT02286817Phase 1Completed
- Sponsor
- Avalo Therapeutics
- Start
- Jan 2015
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, single-blind, single-arm trial of fasoracetam in attention deficit hyperactivity disorder (ADHD), sponsored by Avalo Therapeutics. Primary endpoints: Adverse Events at 4 weeks, Vital Signs at 4 weeks and 3 more. Started Jan 2015; status: completed.
02
Drugs
fasoracetam
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT02286817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02286817.